Shaanxi's Wealthiest Couple Splurges 200 Million to Build Rockets

How does AI joint venture aerospace technology help extend the triangle defense industry chain?

Reporter | Early morning

Editor | Gao Mengyang Zhang Mingyan

Video | Liu Runying

Recently, with the announcement of a joint venture company, Shaanxi’s richest man Yan Jianya and his wife officially threw their chips into the high-barrier commercial aerospace track.

On March 16, Sanjiao Defense (300775.SZ) announced plans to establish Western Aerospace Technology (Shaanxi) Co., Ltd. (tentative name) (hereinafter referred to as: Aerospace Technology) together with Xic Testing, Ruitou Energy, and Shaanxi Aerospace Institute. This joint venture, with a registered capital of 500 million yuan (tentative), focuses mainly on the star-arrow field.

It is worth noting that Yan Jianya and Fan Daidi own two controlling listed companies: Juzo Biotech and Sanjiao Defense.

The investment story of Yan Jianya and his wife is a typical high-tech barrier-driven logic. On the consumer side, led by Fan Daidi, Juzo Biotech has continuously obtained registration certificates for Class III medical devices of recombinant collagen, gaining compliance and B-end market advantages, while also collaborating with foreign companies through technology licensing to “ship out” Chinese original biotech.

On the industrial side, Yan Jianya relies on Sanjiao Defense’s scarce position in large aerospace forgings, extending upstream to titanium alloy materials and downstream to satellite and rocket manufacturing.

At the historic intersection where commercial aerospace is moving toward “star-arrow integration,” Yan Jianya and his wife are attempting to outline a second growth curve in aerospace manufacturing through deep industry-finance collaboration outside the consumer field.

Sitting firmly as the largest shareholder

According to the announcement, all parties in the joint venture show high strategic expectations. From satellite design and manufacturing, rocket R&D, manufacturing, testing, and launching, to satellite telemetry, control, and data application, Aerospace Technology’s business scope essentially covers the entire industry chain.

From the perspective of equity structure, this investment approach is very clear. Sanjiao Defense, under Yan Jianya, is active, investing 200 million yuan for a 40% stake, becoming the largest shareholder.

It is worth mentioning that Sanjiao Defense’s main business involves components for aerospace and aviation equipment.

Regarding the latest progress on major aerospace projects, during an investor relations event on February 2, 2026, a company representative stated: “The aerospace digital integration center project has recently started, and assembly work for the first C919 aircraft’s sections has begun.”

The representative also pointed out that this project will promote the extension of the company’s manufacturing industry chain, increase product added value, strengthen and expand the company’s advantages in the domestic aviation field, and enhance its industrial competitiveness.

From component suppliers to full industry chain coverage, the new joint venture Aerospace Technology is clearly a key step in Yan Jianya’s layout in the aerospace field.

Focusing on other joint venture partners of Aerospace Technology, Xic Testing is a provider of aerospace and high-end equipment inspection, testing, and intelligent manufacturing services, proposing and practicing the “super OEM for commercial aerospace” model.

Shaanxi Aerospace Institute is a state-owned R&D organization led by Northwestern Polytechnical University, jointly established with the Fourth and Sixth Institutes of Aerospace Science and China Aero-Engine Corporation Xian Aero Engine. As the “national team” and “main hub” in the domestic aerospace propulsion field, it is a key link connecting core technology, government resources, and the commercial market.

Sanjiao Defense explicitly states that this investment aims to cultivate new growth points, optimize the company’s industrial structure, improve core competitiveness and sustainable development capacity, and help the company achieve breakthroughs in high-end manufacturing and strategic emerging industries.

The company also issued a risk warning, noting that although there will be no significant impact on current financial data and operating performance in the short term, multiple uncontrollable factors exist in the future, profitability is hard to predict, and there is a risk that investment returns may not meet expectations.

Juzo Biotech “ships out” for new growth

If commercial aerospace is Yan Jianya’s “starry sea,” then Juzo Biotech is the “cash cow” that Professor Fan Daidi and Yan Jianya’s wife and husband are nurturing.

Against the backdrop of declining traffic dividends and price war anxiety in the skincare industry, Juzo Biotech is attempting to evolve from a “consumer goods company” in the eyes of the public into a “medical technology enterprise” through fundamental breakthroughs in technological barriers.

The key turning point lies in the “medical device” license and the continuous approval of key products.

According to information from the National Medical Products Administration’s Center for Drug Evaluation, Shaanxi Juzo Biotech’s application for the “recombinant collagen lyophilized fiber” medical device combination was accepted on June 13, 2025.

On October 23, 2025, Juzo Biotech’s first “recombinant Type I alpha-1 collagen lyophilized fiber” was officially approved for market. Subsequently, on January 15, 2026, the company’s “recombinant Type I alpha-1 collagen and sodium hyaluronate composite solution” was approved as the world’s first such composite implant product.

These two Class III medical device registrations are highly valuable. Previously, in the medical aesthetic injection field, Jinbo Biotech was the only company with all three certificates for recombinant humanized collagen. With Juzo Biotech’s efforts, this situation is expected to further break through.

For Juzo Biotech, moving from “cosmetics” to “medical devices” is not only an upgrade in compliance but also a rebuilding of profit barriers.

In the B-end medical aesthetic market, Juzo Biotech now has the capability to compete directly with Jinbo Biotech. Unlike simple discount marketing, products with medical device qualifications are “hardcore” conditions for opening doors to global medical institutions.

To cope with domestic red ocean competition, Juzo Biotech has also launched a “ship out” strategy. By collaborating with Swedish biotech and medical device company Nordberg Medical, based on Juzo Biotech’s proprietary synthetic biology platform, they jointly promote the global development and commercialization of recombinant collagen in medical aesthetics and biomedicine. This model avoids the long cycle of building channels internally, enabling direct technology monetization and global branding.

As of March 19, 2026, Juzo Biotech’s stock price was HKD 30.86, with a total market value of HKD 33.05 billion.

Yan Jianya and his wife, on one hand, are pushing Juzo Biotech into high-premium professional medical tracks through “industry-research co-creation,” and on the other hand, channeling funds into high-barrier military and aerospace sectors. Although Juzo Biotech’s market value fluctuates, it still forms a stable dual-core with Sanjiao Defense—“one civilian, one military; one light, one heavy.”

(Disclaimer: The content of this article is for reference only and does not constitute investment advice. Investors operate at their own risk.)

Produced by | 21st Century Business Herald 21st Century Economic Report